Literature DB >> 23142620

Binding of single walled carbon nanotube to WT and mutant HIV-1 proteases: analysis of flap dynamics and binding mechanism.

Biswa Ranjan Meher1, Yixuan Wang.   

Abstract

Most of the currently treated HIV-1 protease (HIV-PR) inhibitors have been prone to suffer from the mutations associated drug resistance. Therefore, it is necessary to search for potent alternatives against the drug resistance. In the current study we have tested the single-walled carbon nanotube (SWCNT) as an inhibitor in wild type (WT) as well as in three primary mutants (I50V(PR), V82A(PR) and I84V(PR)) of the HIV-1-PR through docking the SWCNT in the active site region, and then performed all-atom MD simulations for the complexes. The conformational dynamics of HIV-PR with a 20 ns trajectory reveals that the SWCNT can effectively bind to the HIV-1-PR active site and regulate the flap dynamics such as maintaining the flap-flap closed. To gain an insight into the binding affinity, we also performed the MM-PBSA based binding free energy calculations for the four HIV-PR/SWCNT complexes. It was observed that, although the binding between the SWCNT and the HIV-PR decreases due to the mutations, the SWCNTs bind to the HIV-PRs 3-5 folds stronger than the most potent HIV-1-PR inhibitor, TMC114. Remarkably, the significant interactions with binding energy higher than 1kcal/mol focus on the flap and active regions, which favors closing flap-flap and deactivating the active residues of the HIV-PR. The flap dynamics and binding strength information for HIV-PR and SWCNTs can help design SWCNT-based HIV-1-PR inhibitors.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23142620      PMCID: PMC3508351          DOI: 10.1016/j.jmgm.2012.10.001

Source DB:  PubMed          Journal:  J Mol Graph Model        ISSN: 1093-3263            Impact factor:   2.518


  40 in total

1.  Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of Amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease.

Authors:  Hiroyasu Ohtaka; Adrian Velázquez-Campoy; Dong Xie; Ernesto Freire
Journal:  Protein Sci       Date:  2002-08       Impact factor: 6.725

2.  Crystal structures of HIV protease V82A and L90M mutants reveal changes in the indinavir-binding site.

Authors:  Bhuvaneshwari Mahalingam; Yuan-Fang Wang; Peter I Boross; Jozsef Tozser; John M Louis; Robert W Harrison; Irene T Weber
Journal:  Eur J Biochem       Date:  2004-04

3.  Glycosidase inhibition with fullerene iminosugar balls: a dramatic multivalent effect.

Authors:  Philippe Compain; Camille Decroocq; Julien Iehl; Michel Holler; Damien Hazelard; Teresa Mena Barragán; Carmen Ortiz Mellet; Jean-François Nierengarten
Journal:  Angew Chem Int Ed Engl       Date:  2010-08-02       Impact factor: 15.336

4.  Inhibition of a thermophilic deoxyribonucleic acid polymerase by fullerene derivatives.

Authors:  Xianmei Meng; Bo Li; Zhe Chen; Lu Yao; Dongxu Zhao; Xinlin Yang; Min He; Qun Yu
Journal:  J Enzyme Inhib Med Chem       Date:  2007-06       Impact factor: 5.051

5.  Comparison of multiple Amber force fields and development of improved protein backbone parameters.

Authors:  Viktor Hornak; Robert Abel; Asim Okur; Bentley Strockbine; Adrian Roitberg; Carlos Simmerling
Journal:  Proteins       Date:  2006-11-15

6.  Rapid and accurate prediction of binding free energies for saquinavir-bound HIV-1 proteases.

Authors:  Ileana Stoica; S Kashif Sadiq; Peter V Coveney
Journal:  J Am Chem Soc       Date:  2008-01-29       Impact factor: 15.419

7.  Nanoscale enzyme inhibitors: fullerenes inhibit carbonic anhydrase by occluding the active site entrance.

Authors:  Alessio Innocenti; Serdar Durdagi; Nadjmeh Doostdar; T Amanda Strom; Andrew R Barron; Claudiu T Supuran
Journal:  Bioorg Med Chem       Date:  2010-03-15       Impact factor: 3.641

8.  Solution NMR evidence that the HIV-1 protease catalytic aspartyl groups have different ionization states in the complex formed with the asymmetric drug KNI-272.

Authors:  Y X Wang; D I Freedberg; T Yamazaki; P T Wingfield; S J Stahl; J D Kaufman; Y Kiso; D A Torchia
Journal:  Biochemistry       Date:  1996-08-06       Impact factor: 3.162

9.  Energetic basis for drug resistance of HIV-1 protease mutants against amprenavir.

Authors:  Parimal Kar; Volker Knecht
Journal:  J Comput Aided Mol Des       Date:  2012-02-14       Impact factor: 3.686

10.  Optimizing the binding of fullerene inhibitors of the HIV-1 protease through predicted increases in hydrophobic desolvation.

Authors:  S H Friedman; P S Ganapathi; Y Rubin; G L Kenyon
Journal:  J Med Chem       Date:  1998-06-18       Impact factor: 7.446

View more
  5 in total

1.  Molecular dynamics exploration of the binding mechanism and properties of single-walled carbon nanotube to WT and mutant VP35 FBP region of Ebola virus.

Authors:  Yan-Jun Zhang; Jing-Na Ding; Hui Zhong; Chang-Ping Sun; Ju-Guang Han
Journal:  J Biol Phys       Date:  2017-01-21       Impact factor: 1.365

2.  Exploring the drug resistance of V32I and M46L mutant HIV-1 protease to inhibitor TMC114: flap dynamics and binding mechanism.

Authors:  Biswa Ranjan Meher; Yixuan Wang
Journal:  J Mol Graph Model       Date:  2014-12-05       Impact factor: 2.518

3.  Targeting the DENV NS2B-NS3 protease with active antiviral phytocompounds: structure-based virtual screening, molecular docking and molecular dynamics simulation studies.

Authors:  Priyanka Purohit; Sthitaprajna Sahoo; Madhusmita Panda; Partha Sarathi Sahoo; Biswa Ranjan Meher
Journal:  J Mol Model       Date:  2022-10-24       Impact factor: 2.172

Review 4.  Molecular modeling in structural nano-toxicology: interactions of nano-particles with nano-machinery of cells.

Authors:  Naveena Yanamala; Valerian E Kagan; Anna A Shvedova
Journal:  Adv Drug Deliv Rev       Date:  2013-05-28       Impact factor: 15.470

Review 5.  Coronavirus and Carbon Nanotubes: Seeking Immunological Relationships to Discover Immunotherapeutic Possibilities.

Authors:  Elidamar Nunes de Carvalho Lima; Ana Luiza Moraes Octaviano; José Roberto Castilho Piqueira; Ricardo Sobhie Diaz; João Francisco Justo
Journal:  Int J Nanomedicine       Date:  2022-02-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.